It is clinically important to maintain high viability and potency of umbilical cord blood units (CBUs) for transplantation during thawing. In the absence of a standard thawing protocol, this study was designed to develop one based on the consensus practice of transplant centers and address the shortage of dextran 40 thawing solution.
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BACKGROUND: It is clinically important to maintain high viability and potency of umbilical cord blood units (CBUs) for transplantation during thawing. In the absence of a standard thawing protocol, this study was designed to develop one based on the consensus practice of transplant centers and address the shortage of dextran 40 thawing solution.
STUDY DESIGN AND METHODS:
Frozen CBU aliquots were thawed using dextran 40 thawing solution while manipulating temperature and volume of diluent and mode of dilution. The effects of these on CD451 and CD341 cell viability were measured through annexin V and SYTOX green staining. The developed protocol was then used to compare dextran 40 and PLASMA-LYTE A thawing solutions and finally tested on whole CBUs.
RESULTS:
Step-by-step investigations resulted in the development of a protocol that thaws and dilutes CBUs with room temperature diluent to five times the original volume using two sequential dilutions separated by equilibration times. PLASMA-LYTE A diluent provided superior viability of CD451 and CD341 cells than dextran 40 and recovered more colony-forming units. However, both diluents were equally effective in maintaining stability of the thawed CBU for 4 hours. Moreover, the stem cell-enriched CD341CD38-subpopulations appeared more resistant to cryoinjuries than their CD341CD381 counterpart.
CONCLUSION:
The developed thawing protocol recovers viable CD451 and CD341 cells above the standard thresholds and maintains CBU potency. PLASMA-LYTE A for thawing solution proved to be an efficient alternative to dextran 40. Finally, greater dilution should be avoided to maintain the viability of CD451 cells and maximize graft cell dose. S ingle and double umbilical cord blood (UCB) transplantation represent a valuable treatment option in pediatric and adult patients with hematologic malignancies and disorders. [1] [2] [3] [4] [5] Selection of UCB units (CBU) is primarily based on human leukocyte antigen (HLA) matching, precryopreservation total nucleated cell (TNC) counts, and when available, CD341 cell counts and colony-forming unit (CFU) content. Considering the importance of cell dose in ensuring the success of transplantation, the thawing and preparation of UCB for infusion has to be performed such that it minimizes cell loss and maintains the viability of cells important for engraftment. The principal objective of our work was to develop a clinically applicable thaw protocol that would maximize cell viability and recovery for cryopreserved red blood cell (RBC) depleted and plasma-reduced CBUs.
The most commonly used method of UCB preparation at transplant centers is the so-called thaw and dilute protocol that reduces the concentration of the cryoprotectant dimethyl sulfoxide (DMSO) to minimize its toxicity to grafts and side effects to patients. 6 The thaw solution is a standard isotonic saline solution containing human albumin (HA) and dextran 40. Previous studies on UCB viability assessment have traditionally used 7-aminoactinomycin D (7-AAD) staining, 6, [9] [10] [11] [12] since this is the method of assessment in licensed CD34 enumeration kits used by banks to quantify CD341 cells. Being a DNA-binding dye, 7-AAD only stains necrotic cells whose membrane has been damaged enough to allow the stain penetration. 13 However, studies have shown that 7-AAD viability assessment overestimates viability because it fails to detect apoptotic cells. 14, 15 Annexin V, a phospholipid-binding protein, on the other hand, stains translocated phosphatidylserine residues on apoptotic cells. 16 Apoptotic annexin V1 7-AAD-cells represent a significant proportion of CD341 cells (range, 20%-40%) in postthaw samples. 14, 15, 17 Functionally, a positive correlation between loss of CFU and annexin V1 UCB CD341 cells was reported, 15 and annexin V high UCB CD341 cells have minimal engraftment activity. 17 Hence, assessing viability based on annexin V and 7-AAD as done herein provides a more realistic measure of postthaw UCB quality. In this study, we describe the step-by-step development of a UCB thaw protocol based on the consensus practice of UCB thaw and preparation in major Canadian and International transplant centers. Additionally, we confirm and extend results of Cloutier and colleagues 9 on the use of PLASMA-LYTE A as an attractive alternative to dextran 40. We show that in the presence of HA, PLASMA-LYTE A effectively maintains viability of white blood cells (WBCs) and CD341 cells above the thresholds set by regulatory bodies and preserves potency of thawed CBUs.
MATERIALS AND METHODS
CBU processing, aliquot preparation, and freezing A total of 16 CBUs were provided by the Canadian Blood Services public cord blood bank. CBUs used had a minimum volume of 50 mL and a TNC count greater than 0.9 3 10
9
. Most CBUs were excluded from banking due to TNC count inferior to 1.5 3 10 9 . Buffy coat preparation was performed following bank procedures. In short, Hespan (6% hetastarch in 0.9% sodium chloride, B. Braun Medical, Inc.) was added at a volume corresponding to 20% of the CBU. Automated volume reduction and RBC depletion was done using a cell separation system (Sepax-2, Biosafe) set at a final volume of 20 mL. DMSO (5 mL of 55% DMSO 5% dextran 40, Akron Biotech) was added at a rate of 0.33 mL/min at 48C to the buffy coat with a multifunction platform (Smart Max AS310, Biosafe). The buffy coat was then aliquoted into 1-mL aliquots in cryovials, and frozen (approx. 218C/min) overnight at 2808C using a freezing container (Mr. Frosty, ThermoFisher Scientific) and then transferred to vapor phase of liquid N 2 . No significant difference in the viabilities of CD451 cells, CD341 cells, and CFU recovery was found between CBUs frozen either with Mr. Frosty device or a controlled-rate freezer (CryoMed; 218C/min from nucleation to 240 and 2108C/min to 2908C; n 5 3; Fig. S1 , available as supporting information in the online version of this paper). Finally, six CBUs processed and frozen at the Canadian Blood Services Cord Blood Bank were provided for final testing. These units were processed similarly but frozen with a controlled-rate freezer (BioArchive, Cesca Therapeutics) and maintained until use in the BioArchive.
Thawing of aliquoted CBUs
UCB buffy coat aliquots were thawed by holding the cryovial in 378C water after which the contents were gently mixed with either room temperature (RT) or 48C cooled diluent and brought up to a final volume as indicated. Inhouse 10% dextran 40 solution (Pharmacosmos A/S) in 0.9% saline was used due to unavailability of clinical-grade dextran 40. For the head-to-head comparison of PLASMA-LYTE A (Baxter) versus dextran 40, a commercial 10% dextran 40 in 0.9% saline solution was used (BioLife Solutions, Inc.). Dextran solutions were used at final 5% dextran 40 concentration and all thaw solutions were supplemented with 4% HA (25% albumin solution, USP, Grifols Ltd). Unless stated otherwise, thawed CB aliquots were kept at RT for 1 hour before samples were removed for staining.
Staining of thawed CBU samples
UCB TNCs were counted on a hematology Analyzer (pocH-100i, Sysmex Corporation). Briefly, 1.0 3 10 6 nucleated cells were stained with CD34-PE and CD45-APC antibodies (BD Biosciences) for 20 minutes at RT in the dark. RBCs were lysed with 2 mL of ammonium chloride-based lysis solution (BD Biosciences), and the sample was mixed vigorously and incubated for 10 minutes at RT in dark. Next, cells were pelleted (250 3 g/6 min) and suspended in annexin V binding buffer (Life Technologies, ThermoFisher Scientific) followed by staining with annexin V Alexa 488 and a dead cell stain kit (SYTOX AADvanced, ThermoFisher Scientific) following the manufacturer's instructions. Samples were kept on ice after further dilution with annexin V binding buffer and acquired within 1 hour on an acoustic focusing flow cytometer (Attune, Life Technologies, ThermoFisher Scientific).
CD341 cell enumeration
Unless stated otherwise, CD451CD341 cell numbers were extrapolated using the measured frequency of CD451CD341 cells based on International Society of Hematotherapy and Graft Engineering (ISHAGE) guidelines and TNC counts. 18 Reagents (Stem-Kit, Immunotech, Beckman Coulter) were used to measure absolute CD451CD341 cell counts for results presented in 
CFU assay
Postprocessing UCB cells were mixed with RBC aggregation agent (HetaSep, StemCell Technologies) to sediment RBCs. Supernatant was next collected and diluted in Iscove's modified Dulbecco's medium (IMDM; Life Technologies), 2% fetal bovine serum (FBS; HyClone, ThermoFisher Scientific). For postthaw, CBU samples were centrifuged (200 3 g/6 min) and suspended in IMDM-2% FBS. As indicated, some CBUs were processed using an RBC depletion kit (ErythroClear, StemCell Technologies). In short, 80 mL of EyrthroClear reagent was used for 450 mL of thawed CBU samples and processed following the manufacturer's instructions. Two to three different dilutions of CBU based on cell count were prepared in IMDM-2% FBS to obtain reportable number of colonies. CFU assay was carried out using methylcellulose medium (MethoCult Optimum, StemCell Technologies) following manufacturer's instructions. Plates were scored for burst-forming unit-erythroid (BFU-E); granulocyte-macrophage (CFU-GM, CFU-G, and CFU-M); granulocyte, erythroid, macrophage, and megakaryocyte (CFU-GEMM) colonies using a CKX41-inverted phase-contrast microscope (Olympus America).
Statistical analysis
Statistical analyses were performed using computer software (GraphPad InStat, Version 3.00, GraphPad, Inc.). All independent experiments were done with CBU from different donors. Unless stated otherwise, the mean 6 SD are presented. Multigroup comparisons were done by paired analysis of variance (ANOVA) while two-groups comparisons were done with two-tailed paired t tests. p values smaller than 0.05 were considered significant.
RESULTS
Impact of diluent volume and temperature on viability of UCB cells A UCB thaw method was developed based on the consensus practice of UCB thawing in major transplant centers. First, we reviewed procedures from four Canadian centers, three US centers, and one from Germany. The majority used dextran 40-based thaw solution composed of dextran 40 (concentration range, 5.00%-8.33%) and HA (concentration range, 2.50%-4.17%) in saline solution. Moreover, the net dilution of CBU varied from site to site, ranging from 1:1 (twofold) to 1:7 (eightfold). Hence, we first investigated the impact of different dilutions (two, three, four, five, and seven times the buffy coat volume) and different diluent temperatures (RT or 48C) on UCB cell viability and yields obtained with an inhouse dextran 40 thaw solution (5% dextran, 4% HA). We assessed viability of TNCs by flow cytometry using adopted guidelines recommended by the ISHAGE to identify CD451 WBCs and CD341 cells (Fig. 1) . 18 The major modifications adopted were the addition of annexin V stain to identify apoptotic cells, and CD341 cell numbers were extrapolated using the frequency of CD451CD341 and TNC counts. Representative flow cytometry viability analysis for each population is presented in Fig. 1 . We did not observe any significant differences in terms of viability of TNCs and CD451 and CD341 cells between the dilutions after testing three donors; however, for all dilutions tested and for all populations, we observed a strong bias toward higher viability when RT diluent was used for thawing ( Fig. 2A and data not shown) . Indeed, combined analysis of these results for all the dilutions as a function of temperature of diluent demonstrated that thawing with RT diluent resulted in viabilities for CD451 WBCs and CD341 cells that were significantly superior than those obtained with cold diluent (Fig. 2B) . Similarly, thawing with RT diluent produced a higher number of viable CD451 and CD341 cells (Fig. 2C) . Hence, RT diluent was selected for the remainder of the study. In addition, a final fivefold dilution (1:4) was selected for further experiments as it was found to be representative of the consensus of dilutions used in transplant centers.
Enhanced viability through stepwise dilution
Thawing of CBUs with different increasing volumes of diluent did not significantly affect the viability of CD451 cells (data not shown), although a trend (R 2 5 0.94) of small decline in CD341 cells viability was evident with increasing dilution (Fig. 2A) . This is likely due to the damaging effect of sudden changes in osmolality of suspending medium. During thawing, dilution leads to a rapid decrease in intracellular DMSO concentration, which leads to a rapid influx of water into the cells resulting in cell swelling. Swelling greater than 40% of the CD341 cells isotonic volume was reported to lead to loss of viability and loss of potency as measured by the CFU assay. 19 Therefore, we decided to introduce equilibrium steps previously shown to reduce the cytotoxic effect of cell swelling. 19 Four different dilution strategies described in Table 1 were compared, all of which produced the same final dilution but differed in the manner of dilution by having none (Strategy I), two (Strategies II and III), or three (Strategy IV) 15-minute equilibrium steps during dilution. All strategies that included equilibrium steps provided significantly better viabilities for TNCs (Fig. 3A) , and Strategy IV provided greater number of viable TNCs than Strategies I and II (Fig. 3B) . A similar trend was observed for CD451 WBCs although the changes were not significant (Fig. 3C) . With respect to CD341 cell population, they showed minimal differences in viability between the strategies (Fig. 3D) . Strategy III was selected for further experiments since it seemed more practical and more likely to be adopted by cord blood banks and by transplant centers. Besides, no significant differences between this strategy and Strategy IV were observed.
Stability of CBUs thawed with dextran 40 or PLASMA-LYTE A-based diluents
Considering the need for a substitute to clinical-grade dextran 40, we tested the developed thaw protocol using both dextran 40 and PLASMA-LYTE A-based diluents. For this comparison, a newly available GMP-grade dextran 40 solution was used. Viabilities of CD451 and CD341 UCB cells were found similar between our in-house and commercial dextran 40 solutions (data not shown). We also set to compare the stability of CD451 and CD341 cells and the CFUs from the CBUs thawed with both diluents after 30 minutes (baseline) and 2 and 4 hours of storage at RT. CBUs thawed with PLASMA-LYTE A consistently had higher viabilities for both CD451 and CD341 cell populations at each time point and the differences were significant at several time points and highly significant when all time points were combined (Fig. 4A) . Moreover, the viability of CD341 cells remained significantly superior with PLASMA-LYTE A when it was assessed solely based on SYTOX staining as well (Fig. 4B ).
There was no significant decrease in the viability of CD451 WBCs even after 4 hours postthaw with either We also analyzed the impact of the two diluents on the occurrence of apoptotic and necrotic CD451 and CD341 cells. The frequency of CD451 WBCs undergoing apoptosis increased over storage time for CBUs thawed with dextran 40 but not PLASMA-LYTE A though the frequency of annexin V1 CD451 cells was generally slightly higher with PLASMA-LYTE A (11.14-fold, p < 0.01 for combined analysis, data not shown). The decreased viability of CD451 and CD341 cells seen with dextran 40 was largely due to significant increases in the proportion of necrotic cells (Fig. 4C) . The superiority of PLASMA-LYTE A was also apparent by the increased potency of CBUs as shown by the greater number of CFUs at all time points although the differences with dextran 40 were not significant (Fig. 4D) . However, combined analyses of all time points for all CBUs clearly demonstrated that greater numbers of CFUs were associated with PLASMA-LYTE A (Fig. 4E ). Of note, there was modest but nonsignificant decline in the number of CFUs during the 4-hour window for both diluents (Fig. 4D ).
Viability analyses of functionally distinct cell subpopulations in thawed CBUs
We tracked the viability of T cells, B cells, neutrophils, monocytes, CD341CD381, and CD341CD38-cells in thawed CBUs. As expected the population most severely damaged by cryopreservation and thawing was the neutrophils (Fig.  5A ), which were for the most part necrotic (Fig. 5B) , followed by the monocytes, which were equally apoptotic and necrotic (Figs. 5B and 5C ). In contrast, B and T cells were more resistant to cryopreservation and thawing as demonstrated by their significantly greater viabilities and lower frequencies of necrotic and apoptotic cells (Figs. 5A-5C ). Finally, we compared the viability of two subpopulations of CD341 cells through the use of CD38 marker. CD341CD38-cells represented 10.2 6 5.1% of CD341 cells (mean 6 SD, n 5 4) and are significantly enriched in UCB cells with long-term reconstitution activity (i.e., hematopoietic stem cells). Interestingly, the frequency of viable CD341CD38-cells was significantly greater than that of CD341CD381 cells enriched in progenitors and committed CD341 cells (Fig. 5D ). This difference in viability was the result of increased necrosis in the CD341CD381 subpopulation (Fig. 5D ).
Cell viabilities and recoveries with CB bags
Finally, we sought to establish the clinical applicability of the thaw protocol (Strategy III) with PLASMA-LYTE A for Table 1 .
transplant centers and UCB banks by thawing six CBUs obtained from the Canadian Blood Services Public UCB Bank. Measurement of viabilities for CD451 and CD341 cells and potency postthaw are new NetCord-FACT standard requirements. In accordance with clinical practice, viability based on 7-AAD staining and CD341 cell counts were obtained using a licensed kit and the ISHAGE single flow cytometry platform. Baseline postthaw viabilities (i.e., 30 min) for CD451 (50 6 9%) and CD341 (96 6 4%) cells for all CBUs were superior to the NetCord-FACT requirements of at least 40 and at least 70%, respectively.
Moreover, viabilities were not significantly diminished 4 hours postthaw for CD451 cells (50 6 2%, p > 0.05) and CD341 cells (96 6 2%, p > 0.05). The postthaw recoveries (i.e., net number) of TNCs, CD451 WBCs, CD341 cells, and CFUs to respective prefreeze inputs were also calculated at baseline and 4 hours (Fig. 6 ). The recovery of TNCs (p 5 0.09) and CD451 cells (p 5 0.07) tended to be reduced at 4 hours postthaw versus 30 minutes (Fig. 6) . A slight but nonsignificant reduction in the recovery of viable CD341 cells was also observed (p 5 0.41). Moreover, the recoveries of CD341 cells were superior to that seen CFU/mL CFU/mL for CD451 cells and CFUs at both time points (p < 0.01, Fig. 6 ). The outcome of transplantation is dependent on the potency of the transplanted CBU and the CFU assay is one of the best indicators of engraftment potential of grafts. 20, 21 Herein, we tested a new centrifuge-free immunomagneticbased method (ErythroClear) intended for the depletion of RBCs for CFU sample preparation. All CBUs tested met agencies' requirement for CFU growth with an average recovery of CFUs close to 50% at 30 minutes and 4 hours postthaw (Fig. 6) . Finally, the mean recovery of CFU-GM at both time points was 45% (data not shown).
DISCUSSION
This study was initiated to provide transplant centers receiving CBUs from the Canadian Blood Services' Public CB Bank with a recommended thaw protocol that has been demonstrated to maintain viability, functionality, and stability of UCB cells prepared for infusion. The same protocol will be used by the bank for its stability monitoring program. In developing this protocol, we have manipulated a number of different variables found to either differ among transplant centers or not be stated in reported procedures.
Based on our viability assessment using a combination of annexin V and SYTOX stains, we found that thawing with RT diluent resulted in significantly more viable CD451 WBCs and CD341 cells compared to cold diluent. Most of the previous studies on UCB thawing indicate thawing at 378C but failed to communicate the temperature of the diluent or whether they tested this variable. 6, 9, 22, 23 Cold diluent likely slows down the capacity of UCB cells to react to the new osmolarity milieu and leads to cytotoxic swelling. 19 Another nonexclusive explanation is increased stiffness of the cytoskeleton in hyperosmotically stressed cells at 48C, which promotes membrane damage. 24 We have demonstrated that addition of equilibrium steps during thawing can increase viability. However, there were no significant differences in the net number of CD451 and CD341 cells recovered between the three strategies perhaps because only four donors were tested. We selected the simplest strategy so that it can be easily adopted at transplant centers and/or UCB banks. Although not clearly standardized, some sort of sequential dilution tends to be the practice adopted in previous studies. 9, 25, 26 An elaborate study by Woods and coworkers 27 used computer modeling to determine the optimal cryoprotectant addition and dilution for human UCB CD341 cells based on assessment of osmotically induced volumetric responses of these cells. The authors concluded that removal of the cryoprotectant solution over ambient temperature and in a two-step procedure is more effective in avoiding volume excursions beyond the tolerance limits for these cells. It is also believed that different cell types tolerate various ranges of solution osmolarities and therefore are affected differently by osmotic shocks, 27 which accounts in part for the increased necrosis in neutrophils and apoptosis in monocytes. Indeed, these results and others suggest that mature myeloid cells are far more sensitive to osmotic stress than lymphocytes and CD341 cells. In support of this, we compared the viability and recovery of CB CD451 and CD341 cells from CB bags and cryovials after a final five-or 10-fold dilution, with the latter accomplished with an additional twofold dilution done 30 minutes postthaw. These results confirmed our previous observations with a trend of reduced recovery of TNCs (24% vs. fivefold, p 5 0.10, n 5 7) and significant reductions in the viability (25%, p 5 0.003) and recovery (29%, p < 0.002) of CD451 cells (data not shown). In contrast, reductions for CD341 cells were less pronounced (<-3%) and nonsignificant (p> 0.2). Altogether, these results suggest that osmotic stress is more cytotoxic to CD451 cells than low DMSO concentration (2%), and that high dilution should therefore be avoided to maximize graft cell dose. We used the new thaw procedure to test PLASMA-LYTE A as a valid alternative to dextran 40. We consistently observed better performance with the PLASMA-LYTE Abased diluent in terms of viability of CD451 and CD341 cells and CFU potency. These results are opposite to what was reported by Reich-Slotky and coworkers. 10 However, this is most likely due to the fact that their PLASMA-LYTE A-based diluent lacked HA and was instead prepared in combination with ACD-A. Indeed, the importance of HA as a stem cell stabilizing reagent in the thawing solution has recently been clearly documented irrespective of the base diluent. 9 Importantly, the thaw protocol with PLASMA-LYTE A diluent was further tested with whole CBUs processed entirely at a public UCB bank. It was demonstrated to be clinically relevant as it maintained the viability of CD451 WBCs and CD341 cells well above the new standards of greater than 40 and 70% for CD451 and CD341 cells mandated by NetCord-FACT more than 4 hours postthaw. Although it is optimal to infuse the thawed CBU as soon as possible after thawing, there are recommendations of suggested safe time to infusion, which is 4 hours for thawed and diluted RBC-reduced samples. 8 Given processing and cryopreservation differences between UCB banks, it is important for all to determine and validate an acceptable thaw expiration time for their CBUs through a quality assessment program. Herein, we did not observe reductions in the viability of CD451 and CD341 cells in thawed samples using PLASMA-LYTE A diluent over 4 hours, nor any significant reduction in CFU numbers. However, a decline in the total number of viable CD451 cells (p 5 0.07) and a trend for CD341 cells (p 5 0.41) was observed after 4 hours emphasizing the importance of infusing CBU shortly after thawing. The postthaw recovery of TNCs, viable cells, and CFUs obtained with the developed thaw protocol was highly satisfactory. Indeed, the mean recovery of viable 7-AAD-CD341 cells postthaw was 97%, which is considerably greater than some previously reported (45%-75%) 6 ,10,23 but also comparable to others. 9, 15, 26, [28] [29] [30] Moreover, the proportions of annexin V-and SYTOX-CD341 cells of 70% resembled closely that reported with a fourfold dextran 40-HA thaw and dilute protocol. 30 When compared to the protocol developed by Regan and coworkers 6 (twofold dextran 40-HA thaw and dilute), the new procedure provided greater recovery of TNCs and CD341 cells, whereas the recovery of CFUs was superior with the former. The recovery of Viability defined as SYTOX-cells. Mean 6 SD presented (n 5 6), paired ANOVA. **p < 0.01, ***p < 0.001.
CFUs with the new procedure was still high at just under 50% as many studies reported lower recoveries (20%-40%). 7, 15, 29 The stringent nature of the assay, the loss of nucleated cells during RBC depletion, and cell death due to cryoinjuries and osmotic stress are likely responsible for the losses. 31 Interestingly, viability analysis of CD341CD38-subset revealed that this hematopoietic stem cell-enriched subpopulation is far more resistant to freezing and thawing than CD341CD381 cells, which is consistent with results previously reported with adult grafts. 32 The reason for this marked difference is unknown but our results suggest that CD341CD381 cells are more sensitive to cryoinjuries and/ or osmotic stress since half are lost to necrosis during thawing.
In conclusion, we have developed a new thaw protocol based on current clinical practice that includes two sequential dilutions separated by equilibration steps. This protocol supports the recovery of viable cells and potency of CBUs adhering to the new NetCord-FACT standards.
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